PMID- 30443340
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20190306
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 7
DP  - 2018
TI  - Recent advances in understanding and managing myasthenia gravis.
LID - F1000 Faculty Rev-1727 [pii]
LID - 10.12688/f1000research.15973.1 [doi]
AB  - Autoimmune myasthenia gravis (MG) is a neuromuscular junction disorder marked 
      clinically by fatigable muscle weakness and serologically by the presence of 
      autoantibodies against acetylcholine receptors (AChRs), muscle-specific kinase 
      (MuSK), or lipoprotein-related protein 4 (LPR4). Over the past few decades, the 
      mortality of patients with MG has seen a dramatic decline secondary to evolving 
      interventions in critical care and medical management. In the past 2 to 3 years, 
      there have been several changes in standard of care for the treatment of MG. 
      These changes include confirmation of the benefit of thymectomy versus medical 
      management alone in AChR patients and a new US Food and Drug 
      Administration-approved medication for refractory MG. There are also several 
      exciting new prospective drugs in the pipeline, which are in different stages of 
      clinical trial testing.
FAU - Jordan, Allison
AU  - Jordan A
AD  - Department of Neurology, The Ohio State Wexner Medical Center, Columbus, Ohio, 
      USA.
FAU - Freimer, Miriam
AU  - Freimer M
AUID- ORCID: 0000-0001-8282-764X
AD  - Department of Neurology, The Ohio State Wexner Medical Center, Columbus, Ohio, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181031
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
RN  - 0 (Autoantibodies)
SB  - IM
MH  - Animals
MH  - Autoantibodies/immunology
MH  - Combined Modality Therapy/*methods/standards
MH  - Disease Management
MH  - Humans
MH  - Myasthenia Gravis/mortality/*therapy
MH  - Salvage Therapy/methods
MH  - Standard of Care/*trends
PMC - PMC6213783
OTO - NOTNLM
OT  - Eculizumab
OT  - Rituximab
OT  - autoantibodies
OT  - myasthenia gravis
OT  - neuromuscular junction disorders
COIS- Competing interests: Miriam L. Freimer sits on the advisory board for Alexion 
      Pharmaceuticals and has previously received research funding from Ra 
      Pharmaceuticals, Alexion Pharmaceuticals, UCB, and Argenx. Competing interests: 
      Nicholas J. Silvestri has previously consulted for Alexion Pharmaceuticals. No 
      competing interests were disclosed.No competing interests were disclosed.
EDAT- 2018/11/18 06:00
MHDA- 2019/03/07 06:00
PMCR- 2018/10/31
CRDT- 2018/11/17 06:00
PHST- 2018/10/23 00:00 [accepted]
PHST- 2018/11/17 06:00 [entrez]
PHST- 2018/11/18 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
PHST- 2018/10/31 00:00 [pmc-release]
AID - F1000 Faculty Rev-1727 [pii]
AID - 10.12688/f1000research.15973.1 [doi]
PST - epublish
SO  - F1000Res. 2018 Oct 31;7:F1000 Faculty Rev-1727. doi: 
      10.12688/f1000research.15973.1. eCollection 2018.